Beijing Biotech is the lead sponsor of 32 current clinical trials in our China register. 32 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Fludarabine, Cyclophosphamide and EB-DART-NK01. The most-studied condition is Epithelial Ovarian Cancer.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
NCT07502287 · Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma
Drugs: Cyclophosphamide, Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
NCT07480954 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
NCT07480928 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
NCT07641036 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
Drugs: Cyclophosphamide, Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
NCT07523529 · ClinicalTrials.gov ↗ · Advanced Unresectable, Metastatic
Drugs: Cyclophosphamide, Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
NCT07486089 · ClinicalTrials.gov ↗ · Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07467863 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
NCT07627698 · ClinicalTrials.gov ↗ · Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
NCT07523542 · ClinicalTrials.gov ↗ · REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
Drugs: Cyclophosphamide, Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
NCT07462650 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Adenocarcinoma of Colon
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
NCT07500220 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Drugs: Cyclophosphamide, Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07641023 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Advanced/Metastatic
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
NCT07551349 · ClinicalTrials.gov ↗ · Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Drug: Fludarabine |
Phase 1/2 | Recruiting | 2026-02 | China |
|
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
NCT07627711 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
NCT07510815 · ClinicalTrials.gov ↗ · Malignant Pleural Mesotheliomas
Drugs: Cyclophosphamide, Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
NCT07492628 · ClinicalTrials.gov ↗ · Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Drugs: Cyclophosphamide, Fludarabine |
Phase 1 | Recruiting | 2026-03 | China |
|
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
NCT07589517 · ClinicalTrials.gov ↗ · Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
NCT07617805 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
NCT07589530 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
Drug: Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
NCT07510828 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07744256 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
Drug: EB-DART-NK01 |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07480941 · ClinicalTrials.gov ↗ · Glioblastoma, High-grade Glioma, Malignant Glioma
Drugs: Cyclophosphamide, Fludarabine |
Phase 1 | Recruiting | 2026-02 | China |
|
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07551336 · ClinicalTrials.gov ↗ · Malignant Glioma, High-Grade Gliomas, Glioblastoma
|
Phase 1 | Recruiting | 2026-03 | China |
|
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
NCT07641049 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer
Drugs: Cyclophosphamide, Fludarabine |
Phase 1 | Recruiting | 2026-03 | China |
|
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
NCT07598955 · ClinicalTrials.gov ↗ · B2 Thymoma, Thymic Carcinoma
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
NCT07551362 · ClinicalTrials.gov ↗ · Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
NCT07523555 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
NCT07617753 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
NCT07589543 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Drugs: Cyclophosphamide, Fludarabine |
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
NCT07622940 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
NCT07510802 · ClinicalTrials.gov ↗ · Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07480213 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
Drug: EB-DART-NK01 |
Phase 1/2 | Recruiting | 2026-02 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 32 | 32 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Shanghai Gynecologic Oncology Group | 5 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | 1 |
| Klus Pharma | 1 |
Sponsors with the most current trials registered for this condition.
Beijing Biotech is the lead sponsor of 32 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 32 of its 32 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 4 drugs and biologicals as interventions. The most frequent are Fludarabine (13), Cyclophosphamide (11), EB-DART-NK01 (2) and Rimiducid (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.